ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- Key things to know ahead of SK Hynix’s blockbuster US listing
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Immunogen (IMGN) Misses Q3 EPS by 42c
November 3, 2017 6:37 AM EDTImmunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.61), $0.42 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $33.62 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
... More